Bio-Techne Corporation (TECH) Earnings Call Transcripts
Bio-Techne Corporation's Latest Earnings Call - June 25, 2026
In the June 25, 2026 earnings call, Merck announced its definitive agreement to acquire Bio-Techne Corporation for USD 73 per share, marking a significant strategic move in the Life Science sector. The acquisition is expected to be immediately accretive to sales growth and EBITDA margins, with projected cost synergies of approximately EUR 140 million to be realized by 2029. Management maintained a high single-digit growth outlook for Bio-Techne, which is anticipated to enhance Merck's overall growth trajectory in the Life Science segment.
Reported metrics
| Metric | Value |
|---|---|
| Acquisition Price | $73 per share (positive) |
| Cost Synergies | EUR 140 million (positive) |
| EPS Accretion Timeline | Year 3 post-closing (positive) |
| Net Debt to EBITDA Target | Below 3x (positive) |
| Total Addressable Market | $27 billion (positive) |
| Projected Growth Rate | High single-digit (neutral) |
Guidance from management
Management expects the acquisition to be immediately accretive to sales growth and EBITDA margins, with high single-digit growth anticipated for Bio-Techne over the medium term. They also expect to realize EUR 140 million in cost synergies by 2029.
What management said
So Peter, let me start with an answer. First of all, we need to close. So -- and when we close, then we will have a look, point number one, it's -- I want to make sure that we will stay on this specific topic. But yes, I expect that we'll see benefits from the global footprint of Merck. And I'm thinking about region for region, where not only on omnichannel, but region for region, we have very strong capabilities.
Let me quickly start. So very important is for that intended acquisition is the focus on innovation. This is the highest importance for us in M&A is focusing on innovation. This is how it contributes to the sector as well as to Merck as a whole. This is very important to put that at first and maybe then in terms of the potential overlaps and complementary nature, the very complementary nature of that deal, JC, can gi...
What analysts pressed on
Analysts raised concerns about the lack of modeled revenue synergies and the potential for flat growth in Bio-Techne's revenue in the near term. There were questions regarding the confidence in achieving the high single-digit growth outlook without these synergies and the implications of onetime costs on overall profitability.
Main topics on the call
- Strategic Acquisition Announcement — Merck has signed a definitive agreement to acquire Bio-Techne for USD 73 per share, representing a 35% premium over its unaffected share price. This acquisition is expected to be a strategic fit that enhances Merck's Lif...
- Sales Growth Accretion — Management indicated that the acquisition is expected to be immediately sales growth accretive for Merck following closing, with Bio-Techne projected to deliver high single-digit growth over the medium term. CEO Kai Beck...
- Cost Synergies and Margin Improvement — The acquisition is expected to yield approximately EUR 140 million in cost synergies by 2029, which represents about 12% of Bio-Techne's sales. CFO Helene von Roeder highlighted that the transaction would be EBITDA margi...
- Revenue Growth Outlook — Management maintained a high single-digit growth outlook for Bio-Techne, which is not modeled to include any revenue synergies. This cautious approach reflects a focus on closing the deal and assessing growth opportuniti...
Read the full Bio-Techne Corporation transcript (June 25, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Bio-Techne Corporation
Bio-Techne Corporation (TECH) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 141 calls on record spanning January 15, 2020 to June 25, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 141 Bio-Techne Corporation earnings call transcripts on record, spanning January 15, 2020 to June 25, 2026. Based on this history, Bio-Techne Corporation reports quarterly. The most recent call on file is dated June 25, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- TECH
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 141
- First call
- January 15, 2020
- Most recent
- June 25, 2026
- Reporting cadence
- quarterly